Terns Pharmaceuticals announced key milestones for 2026 at the 44th Annual J.P. Morgan Healthcare Conference.
The focus is on advancing TERN-701 for CML treatment and expanding the CARDINAL trial.
The company aims to achieve pivotal dose selection, regulatory interactions, and pivotal trial initiation in 2026.
TERN-701 Progress
Selection of pivotal dose and regulatory interactions planned for mid-2026.
CARDINAL Trial Expansion
Updated and expanded data from the CARDINAL trial expected by the second half of 2026.
Initiation of Pivotal Trial
First pivotal trial for the 2L+ population set to begin in late 2026/early 2027.
Unaudited Cash Reserves
Year-end 2025 unaudited cash reserves of $1.0 billion to provide financial runway into 2031.
- Terns Pharmaceuticals is on track to advance TERN-701 towards pivotal trials with a focus on CML treatment.
- Encouraging safety profile and efficacy data from the CARDINAL trial signal potential for TERN-701.
- The company's financial position is strong, supported by significant unaudited cash reserves.
- Strategic efforts are underway to explore new targets for oncology indications and seek partnerships for pipeline programs.
With a strong focus on advancing TERN-701, Terns Pharmaceuticals is poised for significant milestones in 2026.